Merck: Navigating Patent Cliff and Growth Prospects
Merck faces the challenge of expiring patents while pushing a robust pipeline and disciplined capital moves. This gui...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,804 articlesMerck faces the challenge of expiring patents while pushing a robust pipeline and disciplined capital moves. This gui...
Oracle's latest guidance sparked a sell-off as investors weigh AI-driven capital outlays against cash flow. This arti...
A new survey shows a growing openness among high earners to expatriate, signaling shifting expectations for the U.S. ...
A major biotech takeover bid sets the tone for today’s market. AbbVie’s cash offer for Apogee Therapeutics sent share...
Australia moves to empower its online safety watchdog and raise penalties for breaches of the under-16 social media b...
After 15 years of bullish calls on banks, a veteran analyst pivots to private equity and other alternatives, downgrad...
When CODA reports its Q2 2026 results, the focus shifts from headlines to signals—backlog, margins, and customer wins...
Federal Realty Trust just raised its dividend for the 58th time, signaling steady income for investors. Learn how to ...
The Supreme Court decision clears a path for roughly $180 billion in tariff refunds to importers, yet Goldman Sachs c...
The U.S. and Israel launched airstrikes on Iran after weeks of buildup, triggering immediate market volatility. Oil, ...
Two small modular reactor players, NuScale Power and Oklo, are reshaping how utilities think about clean energy. This...
Horizon Technology Finance trades with a monster yield, but a closer look at late-2025 results reveals pressure on in...